8-K: Anixa Reports Encouraging Ovarian Cancer CAR-T Trial Data

Anixa Biosciences announced encouraging patient survival data and regulatory approval for dose escalation in its Phase 1 ovarian cancer CAR-T clinical trial.

Summary

• Encouraging patient survival data observed in the ongoing Phase 1 ovarian cancer CAR-T clinical trial for lira-cel.
• Regulatory approval granted for a protocol amendment enabling substantial dose escalation beyond the original trial protocol.
• Twelve patients with recurrent ovarian cancer, who failed standard chemotherapy and progressed after two or more prior therapies, have been treated across four dosage levels.
• Seven of these patients have lived beyond their expected median survival of approximately three to four months.
• One patient survived 28 months, three patients survived greater than one year (17, 15, and 14 months), and three others survived 11, 8, and 8 months, respectively.
• Three patients (15, 14, and 8 months) and one additional patient treated more recently are currently alive.
• No dose-limiting toxicities (DLTs) have been observed to date, supporting the decision for dose escalation.
• Dosing may increase from the original range of 1x10^6 to 1x10^8 CAR-positive cells per kilogram of body weight (cells/kg), representing a two-order-of-magnitude increase.
• The amended protocol introduces lymphodepletion (cyclophosphamide and fludarabine) for the next patient cohort to potentially enhance CAR-T expansion, persistence, and activity.
• Anixa's partner, Moffitt Cancer Center, obtained Institutional Review Board (IRB) approval for the protocol amendment.
• Anixa will participate in a Water Tower Research fireside chat on February 10, 2026, at 11:00 am ET to discuss trial observations and 2026 plans.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive update given the encouraging patient survival data in a difficult-to-treat cancer, the clean safety profile, and the significant regulatory approval for dose escalation, indicating strong progress in the clinical trial.

Positives

• Encouraging patient survival data observed in a patient population with recurrent ovarian cancer, which typically has limited therapeutic options and a poor prognosis.
• Seven out of twelve treated patients have lived beyond their expected median survival of approximately three to four months.
• One patient achieved a remarkable survival of 28 months, and three others survived over one year (17, 15, and 14 months), significantly exceeding expectations.
• A clean safety profile has been observed with no dose-limiting toxicities (DLTs) to date.
• Regulatory approval has been granted for a significant dose escalation, allowing for doses up to 100 times higher than the original protocol.
• The direct intra-peritoneal delivery of CAR-T cells may contribute to the favorable safety profile by reducing systemic toxicity while enhancing localized tumor targeting.
• The introduction of lymphodepletion in the amended study design offers a potential pathway to further enhance the efficacy of the CAR-T therapy.

Negatives

• The observed extended survival is described as 'encouraging, albeit anecdotal, evidence' of clinical activity, indicating that definitive efficacy has not yet been established.
• Patients were treated at doses believed to be 'below the optimal therapeutic range,' suggesting current results may not reflect the full potential of the therapy.
• The role of lymphodepletion in solid tumors remains investigational, and its efficacy in this specific context is yet to be fully assessed.

Risks

• Statements that are not historical fact may be considered forward-looking statements, which involve risks, uncertainties, and other factors beyond the company's control.
• Actual results, performance, or achievements may be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements.
• These risks include, but are not limited to, those factors set forth in Item 1A Risk Factors and other sections of the most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K.

Future Outlook

The company plans to advance into higher-dose evaluation under the amended protocol, potentially increasing dosing up to 100 times the original range. The next patient cohort will also receive lymphodepletion to assess its impact on CAR-T expansion, persistence, and activity in solid tumors. Further updates on Anixa's plans for 2026 will be discussed at the upcoming fireside chat.

Management Comments

• "Although these patients were treated at doses we believe are below the optimal therapeutic range, we are encouraged by the number of individuals who have lived far longer than expected." Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences.
• "The absence of dose-limiting toxicities observed thus far has given us the flexibility to safely explore higher dose levels than originally planned." Dr. Robert Wenham, Chair of the Gynecologic Oncology Program at Moffitt and principal investigator of the trial.
• "With regulatory approval now in place, the program is positioned to advance into higher-dose evaluation under the amended protocol. This amendment allows us to further evaluate both safety and potential therapeutic benefit as the study advances." Dr. Robert Wenham.

Industry Context

StockSavvy.ai notes that the direct intra-peritoneal delivery of CAR-T cells, as employed by Anixa, represents a differentiated approach compared to conventional intravenous administration, potentially reducing systemic toxicity and enhancing localized tumor targeting. The investigation into lymphodepletion's role in solid tumors, while routine in hematologic cancers, is a key area of research for improving CAR-T efficacy in challenging solid tumor indications like ovarian cancer. This positions Anixa at the forefront of exploring novel delivery and enhancement strategies for CAR-T in solid tumors.

Comparison to Industry Standards

• The median survival for recurrent ovarian cancer patients who have failed standard chemotherapy and progressed after two or more prior therapies is approximately three to four months. Anixa's observation of multiple patients substantially exceeding this, with one surviving 28 months and others over a year, suggests a potentially significant improvement over current benchmarks for this advanced patient population.
• The absence of dose-limiting toxicities (DLTs) at current dose levels is a positive safety signal, especially when compared to some CAR-T therapies that have faced challenges with systemic toxicities like cytokine release syndrome (CRS) and neurotoxicity.
• The dose escalation up to 100x, combined with lymphodepletion, aligns with strategies used in successful CAR-T therapies for hematologic cancers (e.g., Novartis' Kymriah, Gilead's Yescarta) to optimize cell expansion and persistence, though its application in solid tumors is still evolving.

Stakeholder Impact

• Shareholders: Positive impact due to encouraging clinical trial results, potential for future value creation if the therapy progresses successfully.
• Patients with Recurrent Ovarian Cancer: Potential for a new, effective therapeutic option where current options are limited.
• Moffitt Cancer Center: Strengthened collaboration and potential for pioneering new cancer treatments.
• Employees: Positive morale and continued work on a promising therapy.

Next Steps

• Advance into higher-dose evaluation under the amended protocol.
• Treat the next patient cohort with 1x10^8 cells/kg following lymphodepletion (cyclophosphamide and fludarabine).
• Assess whether lymphodepletion can further enhance efficacy in a localized solid tumor setting.
• Dr. Kumar to discuss observations and 2026 plans at the Water Tower Research Fireside Chat on February 10, 2026.

Key Dates

Recommendation

The filing presents highly encouraging early-stage clinical data for a CAR-T therapy targeting recurrent ovarian cancer, a disease with very poor prognosis and limited treatment options. The observed extended patient survival, particularly with one patient surviving 28 months and others exceeding a year, significantly surpasses the expected median survival for this advanced patient population. Crucially, the absence of dose-limiting toxicities has led to regulatory approval for a substantial 100-fold dose escalation and the incorporation of lymphodepletion, strategies known to enhance CAR-T efficacy. These factors suggest a strong potential for the therapy to demonstrate meaningful clinical benefit as the trial progresses, making it a compelling investment opportunity in the biotechnology sector.

Keywords

Anixa Biosciences, ANIX, ovarian cancer, CAR-T therapy, clinical trial, Phase 1, lira-cel, liraltagene autoleucel, Moffitt Cancer Center, immunotherapy, oncology, biotechnology, dose escalation, lymphodepletion, FSHR, cancer treatment